Morgan Stanley’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $75K | Buy |
63,016
+27,795
| +79% | +$33.1K | ﹤0.01% | 6224 |
|
|
2025
Q1 | $71.5K | Buy |
35,221
+490
| +1% | +$995 | ﹤0.01% | 6153 |
|
|
2024
Q4 | $209K | Sell |
34,731
-1,183
| -3% | -$7.12K | ﹤0.01% | 5768 |
|
|
2024
Q3 | $251K | Buy |
35,914
+18,665
| +108% | +$131K | ﹤0.01% | 5666 |
|
|
2024
Q2 | $100K | Buy |
17,249
+6
| +0% | +$35 | ﹤0.01% | 5966 |
|
|
2024
Q1 | $123K | Sell |
17,243
-34,019
| -66% | -$243K | ﹤0.01% | 5910 |
|
|
2023
Q4 | $252K | Buy |
51,262
+46,319
| +937% | +$228K | ﹤0.01% | 5860 |
|
|
2023
Q3 | $47.3K | Sell |
4,943
-3,562
| -42% | -$34.1K | ﹤0.01% | 6190 |
|
|
2023
Q2 | $110K | Buy |
8,505
+2,881
| +51% | +$37.3K | ﹤0.01% | 5904 |
|
|
2023
Q1 | $71.4K | Buy |
5,624
+4,755
| +547% | +$60.3K | ﹤0.01% | 6138 |
|
|
2022
Q4 | $10K | Buy |
+869
| New | +$10K | ﹤0.01% | 6934 |
|